Crescent Pharma Limited Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Crescent Pharma Limited Pharmaceutical Import Records from India — 6 Products, $11.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Crescent Pharma Limited — Pharmaceutical Importer Profile (2026) | 6 Products, $11.8M Trade | TransData Nexus

Crescent Pharma Limited

Pharmaceutical Importer · United Kingdom · Cardiovascular Focus · $11.8M Total Trade · DGFT Verified

Crescent Pharma Limited is a pharmaceutical importer based in United Kingdom with a total trade value of $11.8M across 6 products in 5 therapeutic categories. Based on 528 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Crescent Pharma Limited sources from 24 verified Indian suppliers, with Unison Pharmaceuticals Private Limited accounting for 31.9% of imports.

Crescent Pharma Limited — Import Portfolio & Supplier Network

Crescent Pharma Limited import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Crescent Pharma Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Unison Pharmaceuticals Private Limited	$6.7M	273	31.9%
Geno Pharmaceuticals Private Limited	$4.3M	250	20.5%
Archimedis Healthcare Private Limited	$941.1K

What Formulations Does Crescent Pharma Limited Import?

Formulation	Value	Ships
Ramipril capsules 10MG	$870.6K	20
Ramipril capsules 2.5MG	$562.9K	19
Ramipril capsules 5MG	$472.1K	14
Xailin night eye ointment 5 GM (lubricating eye ointment)	$366.4K	9
Amlodipine 10 MG tablets2x14tbl	$232.9K	6
Primidone 250MG tablets(5x20)	$155.9K	5
Amisulpride 200 MG tablets (6x10t)bl (amisulpride) (1 nos = 1 packs) b.no.: 2430016, 2430207, 2430208 as per	$140.8K	3
Etoricoxib 90MG 2x14tab	$138.0K	4
Atorvastatin 40MG film coated tablets (Pack of 2x14 tablets) ( 189570 packs	$119.4K	3
Etoricoxib 60MG 2x14tab	$109.4K	3
Gliclazide 80 MG tablets (gliclazide)(2x14t)bl(gliclazide)b.no.2330948 to 2330952,2330997,2331022,2331023 as per	$108.2K	3
Amlodipine 10 MG tablets(2x14t)bl	$103.8K	4
Terbinafine 250 MG tablets(2x14t)bl	$100.0K	2
Solifenacin succin.10MG fc tabs(3x10t	$100.0K	2
Amlodipine 5 MG tablets(2x14t) bl	$100.0K	2

Crescent Pharma Limited imports 693 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ramipril	Cardiovascular	$8.9M	357	6.4%	3
2	Gliclazide	Advanced Diabetes Medications	$1.2M	54	0.4%	15
3	Levothyroxine	Diabetes & Endocrine	$926.4K	94	1.2%	16
4	Terbinafine	Antifungals	$632.6K	15	2.3%	11
5	Diazepam	CNS & Psychiatric	$121.4K	4	1.6%	10
6	Clonazepam	CNS & Psychiatric	$118.9K	4	0.1%	14

Crescent Pharma Limited imports 6 pharmaceutical products across 5 categories into United Kingdom totaling $11.8M.

Crescent Pharma Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Crescent Pharma Limited is a privately held generic pharmaceutical company headquartered in Basingstoke, Hampshire, United Kingdom. Established in 2003, the company has rapidly expanded its operations, becoming one of the largest and fastest-growing independent generic pharmaceutical firms in the UK. Crescent Pharma specializes in the production and marketing of affordable generic medicines, holding over 400 UK Marketing Authorisations and a pipeline of an additional 150 in development.

The company's registered office is located at Key House, Sarum Hill, Basingstoke, Hampshire, RG21 8SR, England. (find-and-update.company-information.service.gov.uk) Crescent Pharma operates multiple manufacturing sites and distribution centers across the UK, including facilities in Andover, Barnsley, Bolton, Mablethorpe, and London. This extensive infrastructure enables the company to effectively supply a wide range of medicines to the UK market, including hospitals, pharmacies, retail outlets, and clinics.

2Distribution Network

Crescent Pharma Limited has established a comprehensive distribution network to ensure the efficient delivery of its products across the United Kingdom. The company owns and operates several manufacturing sites capable of producing both solid and liquid dosage forms. Additionally, Crescent Pharma maintains two standalone warehouses, providing full UK coverage and facilitating timely distribution to various healthcare providers.

The strategic locations of these facilities in Andover, Barnsley, Bolton, Mablethorpe, and London enable Crescent Pharma to effectively manage inventory, storage, and transportation logistics. This infrastructure supports the company's commitment to supplying over 200 million packs to the UK market in 2022, demonstrating its capacity to meet the demands of the National Health Service (NHS) and other healthcare providers.

3Industry Role

Crescent Pharma Limited plays a significant role in the United Kingdom's pharmaceutical supply chain as a primary wholesaler and distributor of generic medicines. The company specializes in the production and marketing of affordable generic medications, holding over 400 UK Marketing Authorisations and a pipeline of an additional 150 in development. Crescent Pharma's products are supplied and used in hospitals, pharmacies, retail outlets, and clinics, contributing to the accessibility and affordability of healthcare in the UK.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Crescent Pharma Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Crescent Pharma Limited's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $11.8 million USD from India, encompassing 528 shipments across six products in five therapeutic categories. The top five imported products include Ramipril ($8.9 million, 6.4% share), Gliclazide ($1.2 million, 0.4% share), Levothyroxine ($926,000, 1.2% share), Terbinafine ($633,000, 2.3% share), and Diazepam ($121,000, 1.6% share).

The substantial reliance on a limited number of suppliers from India indicates a strategic choice to maintain consistent product quality and supply chain efficiency. The top five suppliers—Unison Pharmaceuticals Private Limited, Geno Pharmaceuticals Private Limited, Archimedis Healthcare Private Limited, Acme Generics Private Limited, and Steril-Gene Life Sciences Private Limited—account for 99% of Crescent Pharma's imports from India. This concentration suggests a stable and well-established relationship with these suppliers, which is crucial for ensuring the uninterrupted availability of essential medications in the UK market.

2Supply Chain Resilience

Crescent Pharma Limited's supply chain resilience is bolstered by its strategic partnerships with a select group of Indian suppliers, ensuring a consistent and reliable source of pharmaceutical products. The company's import data reveals a diversified portfolio of 693 unique formulations, indicating a broad range of products sourced from India. This diversity mitigates the risks associated with over-reliance on a single product or supplier, enhancing the overall stability of Crescent Pharma's supply chain.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) serves as the primary regulatory authority overseeing the safety, efficacy, and quality of medicines, medical devices, and blood components for transfusion. The MHRA is responsible for ensuring that pharmaceutical products meet the required standards before they are marketed in the UK. (pharmacopoeia.mhra.gov.uk)

Key legislation governing pharmaceutical imports into the UK includes the Medicines for Human Use (Clinical Trials) Regulations 2004 [SI 2004/1031], which outlines the requirements for importing human medicines. To import a licensed medicine, entities must obtain a Wholesale Distribution Licence (WDA(H)), a Manufacturer's Licence, and a Marketing Authorisation (MA). These licenses ensure that imported medicines comply with UK regulations and are safe for public use. (gov.uk)

2Import Licensing & GMP

Import licensing requirements in the UK are stringent to ensure the safety and efficacy of pharmaceutical products. Companies must obtain a Wholesale Distribution Licence (WDA(H)) and a Manufacturer's Licence to import human medicines. Additionally, a Marketing Authorisation (MA) is required before a medicine can be sold in the UK. If the medicine contains a controlled substance, the Home Office must be contacted for additional permissions. (gov.uk)

Crescent Pharma Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Crescent Pharma Limited's product strategy focuses on providing a diverse range of generic medicines across multiple therapeutic areas, including cardiovascular, advanced diabetes medications, and diabetes & endocrine treatments. The company's import data indicates a significant emphasis on cardiovascular medications, with Ramipril being the top imported product. This focus aligns with the high prevalence of cardiovascular diseases in the UK, addressing a critical area of public health concern.

The importation of advanced diabetes medications and diabetes & endocrine treatments reflects Crescent Pharma's commitment to managing chronic conditions prevalent in the UK population. By offering cost-effective alternatives to branded medications, Crescent Pharma enhances accessibility to essential treatments, supporting the healthcare system's sustainability and improving patient outcomes.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Crescent Pharma Limited

What products does Crescent Pharma Limited import from India?

Crescent Pharma Limited imports 6 pharmaceutical products across 5 categories. Top imports: Ramipril ($8.9M), Gliclazide ($1.2M), Levothyroxine ($926.4K), Terbinafine ($632.6K), Diazepam ($121.4K).

Who supplies pharmaceuticals to Crescent Pharma Limited from India?

Crescent Pharma Limited sources from 24 verified Indian suppliers. The primary supplier is Unison Pharmaceuticals Private Limited (31.9% of imports, $6.7M).

What is Crescent Pharma Limited's total pharmaceutical import value?

Crescent Pharma Limited's total pharmaceutical import value from India is $11.8M, based on 528 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Crescent Pharma Limited focus on?

Crescent Pharma Limited imports across 5 categories. The largest: Cardiovascular (74.7%), Advanced Diabetes Medications (10.1%), Diabetes & Endocrine (7.8%).

Get Full Crescent Pharma Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.